scholarly journals Perennial allergic rhinitis in children: efficiency and safety of using «Ergocetal»

2021 ◽  
pp. 12-16
Author(s):  
T.R. Umanets ◽  
◽  
V.F. Lapshyn ◽  
A.A. Rudnev ◽  
O.I. Pustovalova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Nasal Congestion ◽  
School Age Children ◽  
Perennial Allergic Rhinitis ◽  
Good Tolerance ◽  
Ocular Symptoms ◽  
Positive Therapeutic Effect ◽  
High Adherence ◽  
Key Words Allergic Rhinitis

Purpose — to evaluate the efficacy and safety of levocetirizine («Ergocetal») in children with perennial allergic rhinitis (PAR). Materials and methods. 30 children aged 6–16 years with PAR were examined. All children were prescribed levocetirizine («Ergocetal») 5 mg in the form of tablets once a day for a month for the treatment of PAR. The criteria for the effectiveness of the treatment were: regression of the main nasal and ocular symptoms of PAR (rhinorrhea, nasal congestion, nasal itching, sneezing, itching and redness of the eyes) according to the visual analogue scale (VAS); dynamics of nasal eosinophilia in a smearst from the nasal mucosa. Results. The studies have shown that prescribe of levocetirizine «Ergocetal» in monotherapy for school-age children with mild and intermittent PAR had a positive therapeutic effect on nasal and ocular symptoms, as well as on the intensity of eosinophilic inflammation in the nasal mucosa. Established good tolerance and the absence of side effects of «Ergotal» in the examined children. Conclusions. Therapeutic efficacy, absence of adverse reactions, high adherence to treatment make it possible to recommend levocetirizine («Ergocetal») as monotherapy for mild and intermittent PAR in school children. The research was carried out in accordance with the principles of the Helsinki declaration. The study protocol was approved by the Local Ethics Committee of an participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: allergic rhinitis, treatment, levocetirizine.

scholarly journals INFLUENCE OF THE FUNGAL MICROFLORA ON THE COURSE OF PERENNIAL ALLERGIC RHINITIS IN CHILDREN

2012 ◽  
Vol 9 (6) ◽  
pp. 39-43
Author(s):  
T G Malanicheva ◽  
L F Akhmadieva ◽  
S N Denisova
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Antimicrobial Agents ◽  
Nasal Congestion ◽  
Fungal Colonization ◽  
Perennial Allergic Rhinitis ◽  
Treatment Needs ◽  
Perennial Rhinitis ◽  
Mycological Examination

Background. The purpose of our research was to study the influence of fungal microflora for perennial rhinitis in children to improve the treatment of this disease. Methods. 79 children aged from 7 to 18 years with perennial allergic rhinitis (PAR) with fungal colonization of the nasal mucosa were examined. Patients underwent clinical, allergy, culturing mycological examination of the mucous membranes of the nose, as well as determination of circulating Candida antigen in serum by ampero-metric enzyme immunoassay sensor. Results. Fungi Candida were dominated — in 75,9% of cases in the structure of mycotic colonization, while mold fungi Aspergillus were observed rarely (24,1%). Colonization of the nasal mucosa with fungi Candida in children with PAR makes disease severe and symptoms become more painful that manifest severe nasal congestion, abundant mucus. PAR patients with nasal colonization of the fungi genus Candida in 58,3% of cases in the circulating blood serum had Candida antigen, that indicating the development of invasive Candida infections. That's why therapy of this disease must be improved. Inclusion of antimicrobial agents to the treatment with further traditional therapy of PAR leads to an overall therapeutic effect in 77,1% of cases. Conclusion. In patients with PAR fungal microflora aggravates the disease and the treatment needs to be improved with the inclusion of antibiotics, which lead to high clinical improvement.

Pharmacoeconomic features of the use of drugs used in the treatment of allergic rhinitis

2021 ◽  
pp. 9-16
Author(s):  
Afanasyeva T.G. ◽  
Lavrova N.N. ◽  
Tumentseva V.R.
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Generic Drugs ◽  
Cost Minimization ◽  
Nasal Congestion ◽  
World Health ◽  
Cost Minimization Analysis ◽  
Wide Range

Rhinitis is an inflammation of the nasal mucosa; today, according to the World Health Organization, the prevalence of the disease is 40% of the world's population. Allergic rhinitis is the most common type of chronic rhinitis, affecting 10–20% of the world's population, and the severity of the disease is associated with a significant deterioration in the quality of life, sleep and performance. Allergic rhinitis is an inflammatory disease of the nasal mucosa caused by exposure to an allergen, causing IgE-mediated inflammation. Clinically, the disease is characterized by the following main symptoms: rhinorrhea, sneezing, itching and nasal congestion. Despite the general symptoms of allergic rhinitis, its impact on the quality of life of patients and the significant cost of treatment, including pharmacotherapy, many patients do not adhere to drug treatment regimens due to their insufficient effectiveness in eliminating the emerging symptoms. Pharmacoeconomic research identifies, measures and compares the costs and effects of drug use. This framework includes research methods related to cost minimization, cost-effectiveness, decision analysis, cost of illness, and patient quality of life. This article will consider one of the four main methods for assessing pharmacoeconomics - cost minimization analysis. A cost-minimization analysis is a pharmacoeconomic assessment by comparing the costs of two or more drug alternatives regardless of outcome. Since the pharmaceutical market is represented by a wide range of original, reference and generic drugs for the treatment of allergic rhinitis, an important aspect of our research is the selection of effective and economically acceptable therapy for outpatients.

Allergic Rhinitis

2021 ◽  
Author(s):  
Sonya Marcus
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Congestion ◽  
Treatment Options ◽  
The United States ◽  
Subcutaneous Immunotherapy ◽  
Allergy Testing ◽  
Intranasal Corticosteroids ◽  
Substantial Economic Burden ◽  
Key Words Allergic Rhinitis

Allergic rhinitis is a common condition that affects 10-40% of adults in the United States annually. It has a significant impact on patient quality of life and poses a substantial economic burden on society. Knowledge regarding accurate diagnosis, testing and treatment options are important in the management of this prevalent condition. Treatment options include allergen avoidance, pharmacotherapy and allergy immunotherapy. This review contains 7 figures, 6 tables and 28 references. Key words: allergic rhinitis, rhinorrhea, nasal congestion, intranasal corticosteroids, antihistamines, skin prick allergy testing, intradermal allergy testing, subcutaneous immunotherapy, sublingual immunotherapy, anaphylaxis

Modern H1- antihistamines in the treatment of allergic rhinitis: focus on bilastine

2021 ◽  
Vol 18 (2) ◽  
pp. 66-76
Author(s):  
Alexander V. Emelyanov ◽  
Galina R. Sergeeva ◽  
Evgenia V. Leshenkova
Keyword(s):  
Allergic Rhinitis ◽  
Experimental Studies ◽  
Hepatic Metabolism ◽  
Rapid Onset ◽  
Perennial Allergic Rhinitis ◽  
National Guidelines ◽  
Duration Of Action ◽  
Ocular Symptoms ◽  
H1 Antihistamines ◽  
Adults And Children

The second generation of H1-antihistamines is approved for the stepwise treatment of seasonal and perennial allergic rhinitis in adults and children by international and national guidelines. They reduce the severity of nasal and ocular symptoms of rhinitis and improve the quality of life of patients. Bilastine, a piperidine derivative, is a novel H1-antihistamine. It has a potent and selective effect on H1- receptors and a rapid onset and long duration of action and substantially reduces nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Bilastine has no clinically substantial hepatic metabolism and has a high safety profile: it has no sedative effect, does not affect cognitive functions, has no cardiotoxic effects, and does not interact with alcohol and benzodiazepines in normal and high doses. Tachyphylaxis does not develop despite long-term (up to 1 year) use. Bilastine is registered for clinical use in adults and children aged 12 years. The results of clinical and experimental studies have demonstrated that bilastine has many of the features of modern H1-antihistamines recommended by international guidelines.

Efficacy of Hypertonic Saline Irrigation for Nasal Symptoms in Children with Perennial Allergic Rhinitis: A Randomized Double-Blind Study

2021 ◽  
Vol 104 (10) ◽  
pp. 1570-1577
Keyword(s):  
Allergic Rhinitis ◽  
Side Effects ◽  
Hypertonic Saline ◽  
Symptom Score ◽  
Nasal Congestion ◽  
Nasal Symptom ◽  
Perennial Allergic Rhinitis ◽  
Saline Irrigation ◽  
Nasal Irrigation ◽  
Nasal Cytology

Background: Nasal saline irrigation was an adjunctive therapy of allergic rhinitis (AR). It has been suggested that the use of hypertonic saline (HS) is better than normal saline (NSS) in treatment of AR. Reduction of mucosal edema by hypertonicity induced water transport through nasal mucosa, nasal congestion reduction and mucociliary clearance improvement. Objective: To compare total nasal symptom score (TNSS) between 3% HS and NSS irrigation in perennial allergic rhinitis children. Materials and Methods: The present study was conducted at the Allergy Center of Bhumibol Adulyadej Hospital (BAH), Royal Thai Airforce, Bangkok, Thailand between January and March 2021. Sixty-two perennial AR children were enrolled and categorized in severity level, namely mild, moderate or severe. Subjects were randomized into two groups. Each participant was blind-randomized to nasal irrigation of either 3% HS or NSS twice-daily for 4 weeks by the same investigator. The primary outcome was TNSS improvement between both groups. Secondary outcomes were quality of life, nasal congestion severity improvement, nasal cytology change and side effects. Results: TNSS improvement of 3% HS was more than NSS group (4.03±2.36 versus 2.73±3.06, p=0.034). Nasal congestion was the only symptom that differed significantly between the two groups (1.32±1.01 in 3% HS versus 0.70±1.24 in NSS, p=0.024). Reduction of congestion severity by physical examination, nasal cytology changes and side effects were comparable. Conclusion: Nasal irrigation with 3% HS in children with perennial AR had more improvement than NSS in TNSS., especially nasal congestion. Keyword: Hypertonic saline; Nasal irrigation; Allergic rhinitis; Nasal symptom score

Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis.

1995 ◽  
Vol 152 (6) ◽  
pp. 2059-2067 ◽  
Author(s):  
R U Pawankar ◽  
M Okuda ◽  
S Hasegawa ◽  
K Suzuki ◽  
H Yssel ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Perennial Allergic Rhinitis ◽  
Interleukin 13

Mast cell stabilizers

1992 ◽  
Vol 107 (6_part_2) ◽  
pp. 841-844 ◽  
Author(s):  
Hueston C. King
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell ◽  
Cell Membrane ◽  
Nasal Mucosa ◽  
Nasal Polyps ◽  
Nasal Congestion ◽  
Correct Diagnosis ◽  
Vasomotor Rhinitis ◽  
Ige Mediated ◽  
Exercise Induced

The precise mode of action of the well-studied cromolyn sodium and the newer nedocromil sodium has not been completely elucidated. Because the drugs do not pass the cell membrane and enter the cell, they are virtually not metabolized, do not exert a systemic action, and therefore are associated with only minimal systemic toxicity. To be effective either drug must be applied topically and directly to the nasal mucosa. Proper contact with the nasal mucosa is essential for efficacy; in patients with nasal congestion and secretions, vasoconstrictors or saline lavages are indicated before cromolyn or nedocromil use. Both products are highly effective in patients who have IgE-mediated allergic rhinitis but must be administered prophylactically before exposure to an allergen to prevent development of the allergic event. Neither drug is effective in vasomotor rhinitis, exercise-induced rhinitis, or in the management of nasal polyps. Correct diagnosis is essential before therapy.

Sign in / Sign up

Export Citation Format

Share Document